Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

James Dale Berry, M.D.

Co-Author

This page shows the publications co-authored by James Berry and Merit Cudkowicz.
Connection Strength

3.464
  1. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig (Lond). 2011 Oct; 1(10):1375-1389.
    View in: PubMed
    Score: 0.495
  2. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021 Feb 01; 78(2):186-196.
    View in: PubMed
    Score: 0.236
  3. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021 01; 63(1):31-39.
    View in: PubMed
    Score: 0.232
  4. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med. 2020 09 03; 383(10):919-930.
    View in: PubMed
    Score: 0.230
  5. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020 08; 62(2):156-166.
    View in: PubMed
    Score: 0.220
  6. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology. 2019 12 10; 93(24):e2294-e2305.
    View in: PubMed
    Score: 0.217
  7. Developing multidisciplinary clinics for neuromuscular care and research. Muscle Nerve. 2017 Nov; 56(5):848-858.
    View in: PubMed
    Score: 0.186
  8. Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All? Neurotherapeutics. 2015 Apr; 12(2):376-83.
    View in: PubMed
    Score: 0.158
  9. Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone. Toxicol Rep. 2015; 2:1396-1403.
    View in: PubMed
    Score: 0.155
  10. Predicting success: optimizing phase II ALS trials for the transition to phase III. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar; 15(1-2):1-8.
    View in: PubMed
    Score: 0.146
  11. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond). 2014; 4(7):605-618.
    View in: PubMed
    Score: 0.145
  12. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013; 8(4):e61177.
    View in: PubMed
    Score: 0.138
  13. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr; 14(3):162-8.
    View in: PubMed
    Score: 0.135
  14. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012 Jan; 13(1):110-8.
    View in: PubMed
    Score: 0.125
  15. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. Neuroimage Clin. 2021; 30:102672.
    View in: PubMed
    Score: 0.060
  16. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N Engl J Med. 2020 07 09; 383(2):151-158.
    View in: PubMed
    Score: 0.057
  17. Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities. Muscle Nerve. 2020 08; 62(2):182-186.
    View in: PubMed
    Score: 0.056
  18. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Sci Rep. 2019 11 27; 9(1):17728.
    View in: PubMed
    Score: 0.054
  19. Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. BMC Neurol. 2019 May 29; 19(1):104.
    View in: PubMed
    Score: 0.053
  20. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018 Jul; 5(4):e465.
    View in: PubMed
    Score: 0.049
  21. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 2018 03 21; 97(6):1268-1283.e6.
    View in: PubMed
    Score: 0.048
  22. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):242-249.
    View in: PubMed
    Score: 0.048
  23. Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron. 2014 Oct 01; 84(1):239.
    View in: PubMed
    Score: 0.038
  24. Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discov Today. 2015 Jan; 20(1):65-75.
    View in: PubMed
    Score: 0.038
  25. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron. 2014 Sep 03; 83(5):1043-50.
    View in: PubMed
    Score: 0.038
  26. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep; 15(5-6):362-70.
    View in: PubMed
    Score: 0.037
  27. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014 Apr 10; 7(1):1-11.
    View in: PubMed
    Score: 0.037
  28. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan; 14(1):44-51.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.